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Background: Mammalian sirtuins are homologs to the yeast silent information regulator 2 (Sir2), which is an NAD-
dependent deacetylase. Sirtuins are comprised of 7 proteins, and each has different target proteins. Sirtuin 1 (SIRT1)
plays important roles in maintaining metabolic functions and immune responses, and SIRT3 protects cells from
oxidative stress-induced cell death. Both SIRT1 and SIRT3 are regulated by metabolic status and aging. Hence, SIRT1
and SIRT3 have been researched in metabolic diseases, such as type 2 diabetes mellitus (DM), fatty liver, and heart
diseases. Although these diseases have been increasing, there is little information about relation between the
diseases and SIRT1 and SIRT3 in cats. Therefore we cloned SIRT1 and SIRT3 cDNA, examined mRNA expression in
cat tissues, and investigated the changes in SIRT1 and SIRT3 mRNA expression in peripheral blood leukocyte of cats
fed on HFD for 6 weeks.
Results: Cat SIRT1 and SIRT3 contained a catalytic core region and showed high sequence homology with other
vertebrate SIRT1 (>61.3%) and SIRT3 (>65.9%) amino acids. Real-time polymerase chain reaction analyses revealed that
high expression levels were observed in the liver and skeletal muscle for SIRT1 and in the heart for SIRT3 in cats. In
addition, both cat SIRT1 and SIRT3 expression levels in the pancreas were different between individuals. Cat SIRT1
mRNA expression in peripheral blood leukocytes was significantly elevated in obese cats fed on HFD (P < 0.05).
Conclusions: Cat SIRT1 and SIRT3 genes are highly conserved among vertebrates, and HFD feeding may be related to
SIRT1 mRNA expression mechanisms in cat peripheral blood leukocytes.
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Mammalian sirtuins have been identified as homologs of
the yeast silent information regulator 2 (Sir2) [1], which
is an NAD-dependent deacetylase and related to metab-
olism and longevity in yeast [2]. Seven mammalian
sirtuins are included in the family and each has different
target proteins. Sirtuin 1 (SIRT1) is found primarily in
the nucleus [3] and plays important roles in maintaining
metabolic functions and immune responses through
deacetylation of many substrates, such as forkhead tran-
scription factors [4], peroxisome proliferator-activated
receptor-gamma, coactivator 1-alpha [5] and the p65
subunit of nuclear factor-kappa B (NF-κB) [6]. SIRT3 is
localized to mitochondria [7] and protects cells from oxi-
dative stress-induced cell death by deacetylating isocitrate* Correspondence: tarai@nvlu.ac.jp
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reproduction in any medium, provided the ordehydrogenase 2 [8] and superoxide dismutase 2 [9]. Gene
expression and activity of sirtuins are mainly regulated by
metabolic states and aging [10]. These features of SIRT1
and SIRT3 have been studied in metabolic diseases related
to aging such as type 2 diabetes mellitus (DM) [11,12],
fatty liver [13,14], and heart diseases [15,16].
Prevalence of obesity has increased in cats, and obesity
leads to the development of DM [17] and hepatic lipidosis
[18]. Because the clinical, physiological, and pathological
features of DM in cats closely resemble those in humans,
cats are good animal models for human type 2 DM [19].
However, very little information is available on cat SIRT1
and SIRT3. The aims of this study were to determine the
cDNA sequences, and examine the SIRT1 and SIRT3
mRNA expression in several tissues (Experiment 1), and
to investigate the effects of feeding a high-fat diet (HFD)
on the SIRT1 and SIRT3 expression (Experiment 2) in
cats.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Experiment 1
CDNA cloning of cat SIRT1 and SIRT3
Cat SIRT1 and SIRT3 were cloned from a cat cerebral
cortex cDNA library. The cat SIRT1 cDNA consisted of
a 63 bp 5′-untranslated region (UTR), a 2241 bp open
reading frame (ORF), which encoded a 746 amino acids,
and a 1781 bp 3′-UTR. The calculated molecular mass
of this protein was 81.8 kDa. The cat SIRT3 cDNA se-
quence consisted of a 54 bp 5′-UTR, a 1119 bp ORF,
which encoded 372 amino acids, and a 481 bp 3′-UTR.
The calculated molecular mass of this protein was
40.9 kDa. Both cat SIRT1 and SIRT3 had a potential
polyadenylation signal near the 3′-end (data not shown).
Sequence alignment of the deduced cat SIRT1 and
SIRT3 amino acids indicated that they contained a con-
served catalytic core region and exhibited high hom-
ology with the corresponding region in Sir2 like proteins
(Figure 1). In addition, similar to others, the cat SIRT1
and SIRT3 core region had a zinc finger and NAD+
binding sites. The deduced cat SIRT1 and SIRT3 amino
acids sequences were compared with those of other ver-
tebrates, which revealed high sequence similarity (SIRT1:
95.3% [with dog], 88.0% [with human], 83.2% [with
mouse], 91.3% [with cow], 91.4% [with pig], 67.4%
[with chicken], and 61.3% [with zebrafish]; SIRT3:
83.0% [with dog], 76.6% [with human], 73.7% [with
mouse], 68.9% [with cow], 78.3% [with pig], 66.0%
[with chicken], and 65.9% [with zebrafish]). In the
phylogenic analysis, the evolutionary positions of cat
SIRT1 and SIRT3 were located at the mammalian
SIRT1 and SIRT3 branches, respectively (Figure 2).
Cat SIRT1 and SIRT3 mRNA expression profiles in tissues
SIRT1 and SIRT3 mRNA expression levels in cat tissues
were examined by quantitative real time PCR (q-PCR)
(Figure 3). In two 3-year-old male cats, expression of
both mRNAs were observed in a wide range of tissues,
including the cerebral cortex, heart, kidneys, liver, skel-
etal muscles, pancreas, duodenum, spleen, stomach and
adipose tissue. High expression levels were observed in
the liver and skeletal muscle for SIRT1 and in the heart
for SIRT3 in cats. In addition, both cat SIRT1 and SIRT3
expression levels in the pancreas were different between
individuals.
Experiment 2
Changes in cat SIRT1 and SIRT3 gene expression after HFD
feeding
We fed HFD to healthy cats for 6 weeks to examine the
effect of HFD on cat SIRT1 and SIRT3 gene expression.
Clinical characteristics and plasma metabolite concen-
trations are provided in Table 1. HFD caused significant
increases in BW and hepatocellular injury markers(ALT, AST, and ALP) compared with those at baseline
(P < 0.01). Peripheral blood leukocyte SIRT1 mRNA ex-
pression levels in cats significantly increased (P < 0.05)
compared with those at baseline (Figure 4a). However,
SIRT3 expression was not significantly different between
the two conditions.
Discussion
We successfully cloned the cat SIRT1 and SIRT3 cDNAs.
Sequence alignment of the cat SIRT1 and SIRT3 amino
acids revealed that they contained a conserved catalytic
core domain [20]. This core domain included the motifs
CxxC-(18–20)x-CxxC, which are known to be involved in
zinc fingers, and conserved in all Sir2-like enzymes [21].
The other highly conserved motifs GAG(I/V)SxxxG(I/V)
PDFRS, TQNID, and HG(S/T) create NAD+ binding sites
[22]. SIRT1 and SIRT3 were genetically conserved in the
phylogenetic tree, and may have an enzymatic function in
cats.
SIRT1 and SIRT3 mRNA are expressed in a variety of
tissues in humans [1,7], mice [23], cows, [24] and pigs
[25]. In our study, cat SIRT1 and SIRT3 mRNA was
expressed in various tissues similar to other animals, and
high expression levels were observed in the liver and
skeletal muscle for SIRT1 and in the heart for SIRT3 in
cats. In an SIRT1 heterozygous knockout mice study, ac-
celeration of hepatic steatosis and increased inflamma-
tory gene expressions were observed in the liver [26].
Liver expression of cat SIRT1 may be related to control
fatty acid homeostasis. Since SIRT1 enhance skeletal
muscle insulin sensitivity in mice [27], a high SIRT1
mRNA expression levels in the skeletal muscle is consid-
ered to be related to glucose metabolism in cats. Al-
though SIRT3 deficient mice appear to have normal
activity, they show signs of cardiac hypertrophy at
8 weeks of age [28]. Cat SIRT3 expression in the heart
may be related to protection against cardiac hyper-
trophy. Hypertrophic cardiomyopathy (HCM) is the
most common heart disease in cats and remains a major
cause of morbidity and mortality associated with the risk
of sudden death [29]. Therefore, we think it might be in-
teresting to study the relationship between SIRT3 and
HCM in cats. Additionally, both SIRT1 and SIRT3 ex-
pression levels in the pancreas were different between
individuals. SIRT1 regulate insulin secretion in pancre-
atic β cells [30] and SIRT3 is suppressed in pancreatic is-
lets isolated from human type 2 diabetic patients [31].
Therefore, the expression levels of SIRT1 and SIRT3 in
the pancreas may be considered to be fluctuating by the
metabolic state in cats.
Sirtuins are regulated by nutritional status, for in-
stance, caloric restriction up-regulates SIRT1 [32] and
SIRT3 [8] activity in cultured mammalian cells. In con-
trast, obesity and HFD reduce SIRT1 [13] and SIRT3
Figure 1 Multiple alignment of the deduced amino acid sequences of silent information regulator 2 (Sir2) like family core region. The
deduced amino acid sequences of Saccharomyces cerevisiae (s.c) Sir2 (NP_010242.1), cat (c) sirtuin (SIRT)1 and 3, dog (do) SIRT1 (XP_546130.2) and
3 (XP_855809.1), human (hu) SIRT1 (NP_036370.2) and 3 (NP_036371.1), mouse (mo) SIRT1 (NP_001153061.1) and 3 (NP_001171275.1), cow (co)
SIRT1 (NP_001179909.1) and 3 (NP_001193598.1), pig (pi) SIRT1 (NP_001139222.1) and 3 (NP_001103527.1), chicken (ch) SIRT1 (NP_001004767.1)
and 3, (NP_001186422.1), and zebrafish SIRT1 (XP_001334440.4) and 3 (NP_001073643.1). Starting and ending residue numbers are shown. Black
shaded background indicates 100% homology, whereas gray shaded backgrounds indicate >50% homology. The GAGxSxxxGIPDFR, TQNID, HG(S/T),
and CxxC-(18–20)x-CxxC motifs are indicated with the box. The nucleotide sequences appear in the GenBank database with accession numbers
(caSIRT1) and (caSIRT3).
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regulated in the liver of rat and adipose tissue of mice
[13,33], whereas expression of cat SIRT1 mRNA was up-
regulated in peripheral blood leukocytes by HFD. These
differences in expression patterns may be considered to
be differences in reactivity to HFD between tissues. In
our study, early phase liver inflammation was inferredbecause hepatocellular injury markers were up-regulated
by HFD. Some inflammatory factors are released in
greater amounts from adipose tissue in obese subjects
and cause chronic inflammation in animals [34,35]. HFD
triggers a pro-inflammatory effect, and induces SIRT1
cleavage in adipose tissue [33]. On the other hand, pro-
inflammatory factors enhance the NF-κB signal, and
Figure 2 Phylogenetic tree of the silent information regulator 2 (Sir2) like protein family. The evolutionary tree of cow (co), pig (pi), dog
(do), cat (ca), human (hu), mouse (mo), chicken (ch), zebrafish (ze), and Saccharomyces cerevisiae (s.c) sequences for sirtuin (SIRT)1, SIRT3, and Sir2
was made with the unweighted pair group method with arithmetic mean method using GENETYX-win Ver.9.1.0 (GENETYX Corp). The data base
accession nos. for each amino acid sequence used in this analysis are described in Figure 1. The bars and values of 0.1 in the figure represent
evolutionary distances.
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mechanism [6]. In addition, SIRT1 inhibits inflammatory
pathways in macrophages to regulate inflammatory re-
sponses [36]. Hence we propose the hypothesis that
HFD induces early phase inflammation in tissues such as
liver and adipose tissue, and cat SIRT1 mRNA expres-
sion levels is up-regulated in peripheral blood leukocytes
to suppress inflammation. Since peripheral blood leuko-
cytes SIRT1 mRNA level was increase before total chol-
esterol and glucose level is increase, SIRT1 may become
a candidate marker for early diagnosis of metabolic dis-
eases including obesity in cats.
Conclusions
Our study reveals the full length cat SIRT1 and SIRT3
by cDNA cloning and found that these SIRTs were
highly conserved among vertebrates. And the mRNA ex-
pression analysis revealed that high expression levels
were observed in the liver and skeletal muscle for SIRT1
and in the heart for SIRT3 in cats. In addition, both cat
SIRT1 and SIRT3 expression levels were different be-
tween individuals. Our results provide fundamental in-
formation to reveal the cat SIRT1 and SIRT3 function
about relationship of metabolic diseases. Furthermore,
HFD affected cat SIRT1 mRNA expression in peripheral
blood leukocytes. This represent HFD feeding may be




Cloning of cat SIRT1 and SIRT3 cDNA
Total RNA from tissues of a cat (3-year-old male) was
purchased from Zyagen (San Diego, California). Theamount of RNA was measured by a spectrophotometer
at 260 nm. A cDNA library was prepared from cerebral
cortex RNA using the SMARTer RACE cDNA Ampli-
fication Kit (Clontech, Mountain View, CA). We re-
ferred to the human SIRT1 (GenBank accession number
NM_012238) and SIRT3 (GenBank accession number
NM_012239) cDNA sequences and the cat genome DNA
sequence to design specific primers for cat SIRT1 and
SIRT3. We designed primers 1 and 2 for SIRT1 and 7 and
8 for SIRT3 to obtain the partial cat cDNA sequence
(Table 2). Primers 3 and 9 were to amplify the 3′ ends of
the cat SIRT1 and SIRT3 cDNA sequences respectively,
and primers 4 and 10 were used for 5′ rapid amplification
of cDNA ends polymerase chain reaction (RACE-PCR).
Thirty cycles of PCR were performed at 98°C for 10 s,
60°C for 15 s, and 68°C for 1 min/kb with PrimeSTAR
GXL DNA polymerase (Takara, Shiga, Japan), and
0.2 μM of each of the primers. The amplified fragment
was cloned into the pCR-Blunt II-TOPO vector
(Invitrogen, Carlsbad, CA) and the cDNA sequence was
determined by a commercial DNA sequencing service
(FASMAC Co., Ltd., Kanagawa, Japan).
Quantitative real-time PCR (q-PCR) analysis of SIRT1 and
SIRT3 in various cat tissues
Total RNA (1 μg) was reverse transcribed by QuantiTect
Reverse Transcription Kit (Qiagen, Hilden, Germany).
Genomic DNA was removed by DNase treatment, and
cDNA was synthesized. After inactivating the reverse
transcription reaction by heating at 95°C for 3 min, the
cDNA product was used for q-PCR. Reactions were car-
ried out with Perfect Real Time SYBR Premix Ex Taq II
(Takara) using an ABI 7300 Real Time PCR Sequence
Detection System (Applied Biosystems, Foster City, CA)
Figure 3 Tissue distribution profile of cat sirtuin (SIRT)1 and
SIRT3 mRNA. Expression levels of (a) SIRT1 and (b) SIRT3 in tissues
of two 3- year-old male cat (cat 1; white box bars, cat 2; black box
bars) were determined by quantitative polymerase chain reaction.
Each SIRT1 and SIRT3 value was normalized to that of
beta-actin mRNA.
Table 1 Clinical characteristics and plasma metabolite
concentrations
Baseline Endopint (wk6)
Body weight (kg) 2.6 ± 0.2 3.2 ± 0.3**
Total cholesterol (mg/dL) 100.6 ± 4.3 100.6 ± 9.4
Alanine aminotransferase (U/L) 41.6 ± 4.7 69.6 ± 6.8**
Alkaline phosphatase (U/L) 76.6 ± 14.5 101.2 ± 12.2**
Aspartate aminotransferase (U/L) 24.8 ± 1.3 32.2 ± 1.1**
Lactate dehydrogenase (U/L) 141.8 ± 21.9 131.4 ± 19.9
Serum total protein (g/dL) 6.5 ± 0.2 6.7 ± 0.2
Glucose (mg/dL) 72.6 ± 3.1 77.3 ± 0.6
Blood urea nitrogen (mg/dL) 20.0 ± 1.5 21.4 ± 0.9
Creatinine (mg/dl) 0.9 ± 0.2 1.0 ± 0.1





Figure 4 Effect of a high-fat diet on mRNA levels of cat sirtuin
(SIRT)1 and SIRT3. Prior to the 8-week feeding period (Baseline)
and the conclusion of the 8-week feeding schedule (Endpoint),
SIRT1 (a; white box bars) and SIRT3 (b; black box bars) mRNA
expression levels in peripheral blood leucocytes were determined
by the quantitative polymerase chain reaction assay. Each SIRT1
and SIRT3 value was normalized to that of beta-actin mRNA and
the mean ± standard error of mean (n = 5) for an individual RNA
sample. Statistical analysis was performed using Student’s paired
t-test; *P < 0.05.
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followed by 40 cycles of 95°C for 5 s, and 60°C for 35 s,
in 20 μl reaction volumes containing 2 μl template
cDNA, 0.8 μl primers (0.4 μl of each), 10 μl of SYBR
Premix Ex Taq II, 0.4 μl ROX Reference Dye, and 6.0 μl
distilled water. Primers 5 and 6 and 11 and 12 were
designed from the cloned SIRT1 and SIRT3 sequences
respectively. Primers 13 and 14 were used for beta-
actin mRNA. Following the real-time PCR, the frag-
ment was subjected to dissociation-curve analysis to avoid
nonspecific PCR amplification. Quantitative measurements
were performed by establishing a linear amplification curve
from serial dilutions of the plasmid containing cat SIRT1,
SIRT3, and beta-actin cDNA fragments.
Table 2 Sequences and kind of primers used for polymerase chain reaction
Primer Kind Sequence (5′-3′) Applications Position
SIRT1
1 Sense GAGAGGCAGTTGGAAGATGG RT-PCR 47
2 Antisense CTGTTGCTTCCTGTTTCACG RT-PCR 2275
3 Sense CAACGGTTTGGAAGACGATGCTG 3′ RACE 2156
4 Antisense TCTTCCTCCTCTTCGCCCTCGTCGT 5′ RACE 452
5 Sense CGCCTTGCAATAGACTTCCC q-PCR 897
6 Antisense TGAATTTGTGACAGAGAGATGGTTG q-PCR 1042
SIRT3
7 Sense AGGACCTAGCTGAGCTGATTCG RT-PCR 349
8 Antisense TGTGTGTAGAGCCGCAGAAG RT-PCR 656
9 Sense CTATTTCCTCCGCCTGCTCCACGAC 3′ RACE 603
10 Antisense AGGCCGCTCCTTGGAGACCTGAAGT 5′ RACE 464
11 Sense TGCTTCTGCGGCTCTACAC q-PCR 635
12 Antisense TGTCTCCCCAAAGAACACGA q-PCR 864
Beta-actin
13 Sense GCCAACCGTGAGAAGATGACT q-PCR 353
14 Antisense CCCAGAGTCCATGACAATACCAG q-PCR 481
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Animals
This experiment was conducted with 5 domestic fe-
male cats (mean age, 14.0 ± 1.4 months; age range,
10–30 months; body weight [BW], 2.5 ± 0.1 kg). Vet-
erinarians confirmed that the cats were healthy and
without any clinical manifestations. All cats were in-
dividually housed and maintained for 6 weeks at AQS
Co. Ltd. (Narita, Japan). The cats were fed on HFD,
which was made to order by Nippon Pet Food, Inc.
(Tokyo, Japan). The composition of HFD was mois-
ture (7.0%), crude protein (32.7%), crude fat (23.9%),
crude fiber (0.9%), crude ash (5.5%), and nitrogen free
extract (29.9%). The caloric content was 4660 kcal/kg.
The fatty acid composition of HFD was 14:0 (1.3%), 14:1
(0.4%), 15:0 (0.2%), 16:0 (22.6%), 16:1 (2.3%), 17:0 (0.4%),
17:1 (0.3%), 18:0 (23.1%), 18:1 (35.7%), 18:2n-6 (10.9%),
18:3n-3 (0.4%), 20:0 (0.5%), 20:1 (0.3%), 20:4n-6 (0.2%),
22:0 (0.2%), and unidentified (1.2%). The cats were fed the
diet ad libitum for their daily energy requirement (DER)
from 9:00 AM to 8:30 AM the next day. Any surplus diet
was removed at 4:00 PM a day prior to blood sampling.
DER was calculated as 1.4 × resting energy requirement
(RER) (BW0.75 × 70). RER was based on BW before the
meal at 9:00 AM. Cats were housed in individual cages
and provided with water ad libitum. The animal room
was maintained at 24 ± 2°C and 55 ± 10% relative humidity
on a 12:12 h light: dark cycle (lights on from 8:00 AM to
8:00 PM). Approval for this study was provided by the
Nippon Veterinary and Life Science University Animal
Research Committee.Blood sampling
Pre-prandial blood samples (4–5 ml) were withdrawn
from the jugular vein of cats without sedation prior to
the 6 week feeding period (Baseline); 2.5 ml of this blood
was collected in PAX gene RNA tubes (PreAnalytiX,
Hombrechtikon, Switzerland) for RNA stabilization,
preservation, and sample transport, and the remainder
was collected in heparinized tubes, for immediate centri-
fugation at 1500 × g for 10 min at 4°C to obtain plasma,
which was stored at −30°C until analysis. At the conclu-
sion of the 6 week feeding schedule (Endpoint), pre-
prandial blood (5 ml) was withdrawn again from the
same site and treated in the same manner.
Plasma metabolite and hepatic injury marker enzyme
analysis
Plasma total cholesterol, total protein, glucose, blood
urea nitrogen, and creatinine concentrations as well as
alanine aminotransferase (ALT), alkaline phosphatase
(ALP), asparate aminotransferase (AST), and lactate
dehydrogenase activities were determined using an
autoanalyzer (AU680, Beckman Coulter, CA, USA).
q-PCR analysis of peripheral blood leukocyte mRNA
Total leukocyte RNA was extracted from the blood sam-
ples using TRIzol (Invitrogen), according to the manu-
facturer’s protocol. RNA concentration was assessed by
spectrophotometer at 260 nm, and the presence of iso-
lated RNA was assessed by native agarose gel electro-
phoresis on a 0.8% agarose gel. The cDNA synthesis and
q-PCR analysis were performed as described above.
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Data are presented as mean ± standard error of mean
(SEM) and were analyzed using Student’s paired t-test.
All analyses were performed using GraphPad Prism
(GraphPad Software, San Diego, CA). A P < 0.05 was
considered significant.
Competing interests
None of the authors has any financial or personal relationships that could
inappropriately influence or bias the content of the paper.
Authors’ contributions
SI designed the study, performed experiments, analyzed data, and drafted
the manuscript. GL, MF, HT, and NM participated in data collection and
experimental procedure. IY helped with study design and data analysis. TA
contributed to the study design and helped with editing and revision of the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors would like to thank Enago (www.enago.jp) for the English
language review.
Received: 23 May 2013 Accepted: 23 September 2013
Published: 27 September 2013
References
1. Frye RA: Characterization of five human cDNAs with homology to the
yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may
have protein ADP-ribosyltransferase activity. Biochem Biophys Res
Commun 1999, 260(1):273–279.
2. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin
RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA: Small molecule
activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature
2003, 425(6954):191–196.
3. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I: Evolutionarily
conserved and nonconserved cellular localizations and functions of
human SIRT proteins. Mol Biol Cell 2005, 16(10):4623–4635.
4. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE,
Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP,
Sinclair DA, Alt FW, Greenberg ME: Stress-dependent regulation of FOXO
transcription factors by the SIRT1 deacetylase. Science 2004,
303(5666):2011–2015.
5. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P: Nutrient
control of glucose homeostasis through a complex of PGC-1alpha and
SIRT1. Nature 2005, 434(7029):113–118.
6. Zhang HN, Li L, Gao P, Chen HZ, Zhang R, Wei YS, Liu DP, Liang CC:
Involvement of the p65/RelA subunit of NF-kappaB in TNF-alpha-induced
SIRT1 expression in vascular smooth muscle cells. Biochem Biophys Res
Commun 2010, 397(3):569–575.
7. Onyango P, Celic I, McCaffery JM, Boeke JD, Feinberg AP: SIRT3, A human
SIR2 homologue, is an NAD-dependent deacetylase localized to
mitochondria. Proc Natl Acad Sci U S A 2002, 99(21):13653–13658.
8. Someya S, Yu W, Hallows WC, Xu J, Vann JM, Leeuwenburgh C, Tanokura M,
Denu JM, Prolla TA: Sirt3 Mediates reduction of oxidative damage and
prevention of age-related hearing loss under caloric restriction. Cell 2010,
143(5):802–812.
9. Qiu X, Brown K, Hirschey MD, Verdin E, Chen D: Calorie restriction reduces
oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab 2010,
12(6):662–667.
10. Longo VD, Kennedy BK: Sirtuins in aging and age-related disease. Cell
2006, 126(2):257–268.
11. Banks AS, Kon N, Knight C, Matsumoto M, Gutiérrez-Juárez R, Rossetti L, Gu
W, Accili D: SirT1 Gain of function increases energy efficiency and
prevents diabetes in mice. Cell Metab 2008, 8(4):333–341.
12. Jing E, Emanuelli B, Hirschey MD, Boucher J, Lee KY, Lombard D, Verdin
EM, Kahn CR: Sirtuin-3 (Sirt3) regulates skeletal muscle metabolism
and insulin signaling via altered mitochondrial oxidation and reactive
oxygen species production. Proc Natl Acad Sci U S A 2011,
108(35):14608–14613.13. Deng XQ, Chen LL, Li NX: The expression of SIRT1 in nonalcoholic fatty
liver disease induced by high-fat diet in rats. Liver Int 2007, 27(5):708–715.
14. Kendrick AA, Choudhury M, Rahman SM, McCurdy CE, Friederich M, Van
Hove JL, Watson PA, Birdsey N, Bao J, Gius D, Sack MN, Jing E, Kahn CR,
Friedman JE, Jonscher KR: Fatty liver is associated with reduced SIRT3
activity and mitochondrial protein hyperacetylation. Biochem J 2011,
433(3):505–514.
15. Tanno M, Kuno A, Yano T, Miura T, Hisahara S, Ishikawa S, Shimamoto K,
Horio Y: Induction of manganese superoxide dismutase by nuclear
translocation and activation of SIRT1 promotes cell survival in chronic
heart failure. J Biol Chem 2010, 285(11):8375–8382.
16. Pillai VB, Sundaresan NR, Kim G, Gupta M, Rajamohan SB, Pillai JB, Samant S,
Ravindra PV, Isbatan A, Gupta MP: Exogenous NAD blocks cardiac
hypertrophic response via activation of the SIRT3-LKB1-AMP-activated
kinase pathway. J Biol Chem 2010, 285(5):3133–3144.
17. O’Brien TD: Pathogenesis of feline diabetes mellitus. Mol Cell Endocrinol
2002, 197(1–2):213–219.
18. Armstrong PJ, Blanchard G: Hepatic lipidosis in cats. Vet Clin North Am
Small Anim Pract 2009, 39(3):599–616.
19. Henson MS, O’Brien TD: Feline models of type 2 diabetes mellitus. ILAR J
2006, 47(3):234–242.
20. Sanders BD, Jackson B, Marmorstein R: Structural basis for sirtuin function:
what we know and what we don’t. Biochim Biophys Acta 2010,
1804(8):1604–1616.
21. Sherman JM, Stone EM, Freeman-Cook LL, Brachmann CB, Boeke JD, Pillus L:
The conserved core of a human SIR2 homologue functions in yeast
silencing. Mol Biol Cell 1999, 10(9):3045–3059.
22. Min J, Landry J, Sternglanz R, Xu RM: Crystal structure of a SIR2 homolog-
NAD complex. Cell 2001, 105(2):269–279.
23. Shi T, Wang F, Stieren E, Tong Q: SIRT3, A mitochondrial sirtuin
deacetylase, regulates mitochondrial function and thermogenesis in
brown adipocytes. J Biol Chem 2005, 280(14):13560–13567.
24. Ghinis-Hozumi Y, González-Gallardo A, González-Dávalos L, Antaramian A,
Villarroya F, Shimada A, Varela-Echavarría A, Mora O: Bovine sirtuins: initial
characterization and expression of sirtuins 1 and 3 in liver, muscle, and
adipose tissue. J Anim Sci 2011, 89(8):2529–2536.
25. Jin D, Tan HJ, Lei T, Gan L, Chen XD, Long QQ, Feng B, Yang ZQ: Molecular
cloning and characterization of porcine sirtuin genes. Comp Biochem
Physiol B Biochem Mol Biol 2009, 153(4):348–358.
26. Xu F, Gao Z, Zhang J, Rivera CA, Yin J, Weng J, Ye J: Lack of SIRT1
(mammalian sirtuin 1) activity leads to liver steatosis in the SIRT1+/−
mice: a role of lipid mobilization and inflammation. Endocrinology 2010,
151(6):2504–2514.
27. Schenk S, McCurdy CE, Philp A, Chen MZ, Holliday MJ, Bandyopadhyay GK,
Osborn O, Baar K, Olefsky JM: Sirt1 Enhances skeletal muscle insulin
sensitivity in mice during caloric restriction. J Clin Invest 2011,
121(11):4281–4288.
28. Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, Gupta MP: Sirt3
Blocks the cardiac hypertrophic response by augmenting Foxo3a-
dependent antioxidant defense mechanisms in mice. J Clin Invest 2009,
119(9):2758–2771.
29. Abbott JA: Feline hypertrophic cardiomyopathy: an update. Vet Clin North
Am Small Anim Pract 2010, 40(4):685–700.
30. Bordone L, Motta MC, Picard F, Robinson A, Jhala US, Apfeld J, McDonagh
T, Lemieux M, McBurney M, Szilvasi A, Easlon EJ, Lin SJ, Guarente L: Sirt1
Regulates insulin secretion by repressing UCP2 in pancreatic beta cells.
PLoS Biol 2006, 4(2):e31.
31. Caton PW, Richardson SJ, Kieswich J, Bugliani M, Holland ML, Marchetti P,
Morgan NG, Yaqoob MM, Holness MJ, Sugden MC: Sirtuin 3 regulates
mouse pancreatic beta cell function and is suppressed in pancreatic
islets isolated from human type 2 diabetic patients. Diabetologia 2013,
56(5):1068–1077.
32. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz KT,
Gorospe M, de Cabo R, Sinclair DA: Calorie restriction promotes
mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004,
305(5682):390–392.
33. Chalkiadaki A, Guarente L: High-fat diet triggers inflammation-induced
cleavage of SIRT1 in adipose tissue to promote metabolic dysfunction.
Cell Metab 2012, 16(2):180–188.
34. Hotamisligil GS: Inflammation and metabolic disorders. Nature 2006,
444(7121):860–867.
Ishikawa et al. BMC Veterinary Research 2013, 9:187 Page 8 of 8
http://www.biomedcentral.com/1746-6148/9/18735. Laflamme DP: Companion animals symposium: obesity in dogs and cats:
what is wrong with being fat? J Anim Sci 2012, 90(5):1653–1662.
36. Yoshizaki T, Schenk S, Imamura T, Babendure JL, Sonoda N, Bae EJ, Oh DY,
Lu M, Milne JC, Westphal C, Bandyopadhyay G, Olefsky JM: SIRT1 Inhibits
inflammatory pathways in macrophages and modulates insulin
sensitivity. Am J Physiol Endocrinol Metab 2010, 298(3):E419–E428.
doi:10.1186/1746-6148-9-187
Cite this article as: Ishikawa et al.: Change in mRNA expression of sirtuin
1 and sirtuin 3 in cats fed on high fat diet. BMC Veterinary Research
2013 9:187.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
